Objective To investigate the preventive effect and safety of low-dose tirofiban in early neurological de-terioration(END)after acute ischemic stroke(AIS)intravenous thrombolysis(IVT).Methods From July 2017 to September 2019,144 patients with AIS who received intravenous thrombolysis with alteplase in a hospital,and no intracranial hemor-rhage was found after re-examination of head CT 1 h after thrombolysis and then decided whether to use tirofiban antiplatelet therapy according to the wishes of patients and their families,which were divided into an observation group and a control group.The baseline data,END,symptomatic intracerebral hemorrhage(sICH),the incidence of systemic bleeding,and mor-tality were compared between the two groups.The prognoses of patients in both groups at 3 months after IVT were assessed.Results The incidence of END in the observation group was 7.87％and 20.00％in the control group,and the difference was statistically significant(x2=4.576,P=0.032).There were no significant differences in sICH,systemic bleeding,and mor-tality between the observation group and the control group(all P＞0.05).CPI was present in 85.39％(76/89)of patients in the observation group 24 hours after intravenous thrombolysis,and 70.91％(39/55)in the control group,and the difference be-tween the two groups was statistically significant(x2=4.434,P=0.035).DFI occurred in 2 cases in the observation group and 9 cases in the control group,and the difference was statistically significant(x2=9.601,P=0.002).After 3 months of intrave-nous thrombolysis,the good prognosis rate was 70.79％in the observation group and 52.73％in the control group,and the dif-ference was statistically significant(x2=4.805,P=0.028).Conclusion The early combination of intravenous thrombolysis combined with low-dose tirofiban in the treatment of AIS is safe and effective,which can significantly reduce the deteriora-tion of early neurological function,and the short-term prognosis is good.
维普
万方数据
